Public Health Specialist - Technical Support Unit

PATH appoints Dr. Jeremy Farrar as Chief of Asia, Middle East, and Europe regional division. September 9, 2026 by PATH Geneva, Switzerland - PATH is pleased to announce the appointment of Dr. Jeremy Farrar, a globally recognized leader in public health and clinical medicine, as Chief of its Asia, Middle East, and Europe regional division. In this role, Dr. Farrar will join PATH's Executive Leadership Team and oversee the organization's work across a dynamic and critical set of regions central to advancing global health. He will join the organization on October 1 and be based in Geneva. Dr. Farrar brings decades of experience at the forefront of global health, including leadership roles as Director of the Clinical Research Unit at the Hospital for Tropical Diseases in Vietnam, Assistant Director-General at the World Health Organization (WHO), and Director of Wellcome. Throughout his career, he has led transformative efforts at the intersection of clinical research, public health, and innovation. His work has spanned infectious diseases, noncommunicable diseases, emerging health threats, pandemic preparedness, workforce development, and health systems strengthening to address some of the world's most pressing health challenges. At PATH, Dr. Farrar will lead the organization's work across Asia, the Middle East, and Europe, deepening partnerships with local communities, governments, multilateral organizations, academic institutions, private-sector organizations, and philanthropic partners to advance sustainable health solutions. He will work closely with PATH's country and regional teams to support locally driven priorities and strengthen collaboration across the region. "Joining PATH at this moment is a very exciting opportunity," said Dr. Farrar. "For nearly 50 years, PATH has been recognized for bringing scientific excellence to some of the most complex health challenges facing communities that have too often been overlooked. This is a pivotal moment for global health, and an important moment to sharpen how innovation is translated into public health impact. Doing so will require us to address today's challenges with both urgency and ambition, anticipating and preparing for future changes in national and global health, and ensuring broader access to science and innovation. I look forward to contributing to that effort." PATH President and CEO Nikolaj Gilbert welcomed the appointment as a key step in advancing the organization's strategic priorities. "Jeremy is an exceptional leader, and we're very pleased to welcome him to PATH," said Gilbert. "He brings deep scientific expertise and a strong track record of working in partnership to address complex health challenges. In addition to his many professional achievements, he possesses deep knowledge of the realities that prevent access, the people that make health care possible, and the need for PATH's mission of ensuring breakthrough innovations reach all who need them." Dr. Farrar's appointment strengthens PATH's ability to translate innovation into public health impact in close partnership with the communities and health systems they are designed to serve. He will lead efforts to deepen regional connections, ensuring that solutions are not only scientifically robust, but also relevant, accessible, and impactful where they are needed most. Notes to editors For all media inquiries and interview requests: Lauren Grella, Senior Director Marketing and Communications, PATH, [email protected] About PATH PATH is a global nonprofit advancing health innovations for the people who need them most. With nearly 50 years of experience, a global team of experts, and trusted partnerships spanning 70+ countries, PATH turns breakthroughs into better health for millions every single year.

New SARS-CoV-1 antibody available for vaccine researchers. A collaboration between PATH, Baylor College of Medicine and the Medicines and Healthcare products Regulatory Agency (MHRA) has made a monoclonal antibody (mAb) specific for SARS-CoV-1 available to researchers globally. This mAb can support the development of vaccines for SARS-CoV-1 and its evolving variants, as well as future characterization of novel and multivalent coronavirus vaccines. SARS-CoV-1, responsible for the 2003 SARS outbreak and a cousin of the SARS-CoV-2 virus that causes COVID-19, is a respiratory virus with a high mortality rate. There currently is no licensed vaccine to protect against the disease, despite its pandemic potential. In addition, there are limited SARS-CoV-1 specific antibodies available for vaccine development or therapeutic indications. Through this collaboration, scientists from Baylor produced high-quality recombinant SARS-CoV-1 RBD proteins, vaccinated mice, and tested selected mAbs for their functionality. The use of various techniques to characterize the binding sites and pseudovirus neutralization helped establish a toolbox of mAbs with identified key epitopes within the RBD and discriminate vaccine antigens. Selected hybridoma cultures were shipped to PATH for further screening and down-selection, validation, scale-up production, and distribution. Manufacturers can potentially use the resulting mAb to quantify SARS-CoV-1 spike protein in complex vaccine formulations. These efforts were conducted by: * Dr. Jeroen Pollet, associate professor in pediatric tropical medicine at Baylor; * Dr. Wen-Hsiang Chen, associate professor in pediatric tropical medicine at Baylor; * Dr. Uli Strych, associate professor in pediatric tropical medicine at Baylor and director for strategic initiatives and program development of the Texas Children's Center for Vaccine Development; and * Dr. Maria Elena Bottazzi, senior associate dean of the National School of Tropical Medicine at Baylor and co-director of the Texas Children's Center for Vaccine Development. "Access to well-characterized reference antibodies is essential for evaluating the much-needed emerging pan-coronavirus vaccine candidates and ensuring consistent product development across laboratories," Strych said. "We are pleased that this collaboration has made this resource broadly available to support coronavirus vaccine research worldwide." A full characterization report will be provided along with the antibody, detailing the specificity across different antigens and vaccine formats, based on data produced by Baylor and PATH. To help ensure equitable access, the antibody generated is available for a small handling charge and the cost of shipping for use by vaccine researchers and manufacturers who are developing vaccines for use in countries with low- and middle-income economies. Providing these open resources is one component of PATH's ongoing work with partners to advance the development of vaccines that are low-cost, broadly protective and tailored for use in low-resource settings. The SARS-CoV-1 antibody is available from MHRA via its online repository and distribution center. Visit www.nibsc.org or contact [email protected]. "Making this antibody available to the global vaccine development and manufacturing community - at minimal cost for vaccines targeted toward low-resource economies - can help clear hurdles and accelerate efforts to bring a SARS-CoV-1 vaccine to market," said Dr. Jessica White, PATH senior scientist, Vaccine Formulation. "Though the COVID-19 pandemic is over, coronaviruses have not gone away and this will be a helpful too for future pandemic responses. PATH is proud to be part of this fruitful collaboration and to be supporting researchers in their work to expand coronavirus vaccine development." PATH, Baylor and the MHRA previously collaborated to make SARS-CoV-2 antibodies specific to the Wuhan, Omicron, and Delta variants available to researchers. Funding for SARS-CoV-1 antibody development was provided to PATH from the Coalition for Epidemic Preparedness Innovations.

New typhoid conjugate vaccine from EuBiologics receives WHO prequalification. August 26, 2026 by PATH This important milestone could provide countries with an additional option for typhoid vaccination and can contribute to a sustainable supply of typhoid conjugate vaccines. Seattle, United States and Seoul, Republic of Korea - EuTYPH-C Inj.(R) Multi-dose, a new typhoid conjugate vaccine (TCV) manufactured by EuBiologics in the Republic of Korea, has been prequalified by the World Health Organization (WHO). This brings the total number of WHO-prequalified TCVs to five and represents another important step toward expanding global access to typhoid vaccination. Demand for TCVs is high in typhoid-endemic countries. TCVs, recommended by WHO, have several advantages compared to older typhoid vaccines; notably, they provide longer-lasting protection, only require one dose, and can be given to children as young as 6 months of age, allowing for inclusion in routine immunization. However, TCVs are not always affordable or accessible for low-income countries. Development of additional TCVs from diverse manufacturers can help strengthen supply, support greater affordability, and expand access for countries seeking to introduce TCVs as part of their typhoid prevention and control strategies. "WHO prequalification of EuTYPH-C Inj.(R) Multi-dose is an important milestone in EuBiologics' commitment to expanding access to high-quality vaccines worldwide," said Howard Her, Clinical Development Team Leader at EuBiologics. "We are grateful to RIGHT Foundation, PATH, and all of our clinical and development partners whose collaboration made this achievement possible. We look forward to contributing to a sustainable global supply of typhoid conjugate vaccines and helping countries protect more children and communities from typhoid fever." WHO prequalification - a designation confirming that a vaccine meets strict international standards for quality, safety, and efficacy - was supported by rigorous clinical studies in the Philippines, Kenya, and Senegal that demonstrated strong safety and immunogenicity. Importantly, WHO prequalification enables EuTYPH-C Inj.(R) Multi-dose to be considered for procurement by United Nations agencies and for use in Gavi, the Vaccine Alliance-supported immunization programs. It is approved for use in children and adults aged 6 months to 45 years. PATH supported the EuTYPH-C Inj.(R) Multi-dose Phase 3 clinical study in Kenya and Senegal, as well as supported EuBiologics through WHO prequalification pre-submission meetings and clinical assessment responses. PATH is now collaborating with EuBiologics on a follow-up study evaluating the persistence of immune responses approximately 3 to 3.5 years after vaccination among children who participated in the previous Phase 3 study. Final results from the study are expected in early 2027. "The ongoing evolution of new TCVs onto the global market is crucial for establishing sustainable, accessible supply in the regions with the greatest need. Prequalification of EuTYPH-C Inj.(R) Multi-dose marks the moment when rigorous clinical research transforms into real, lifesaving protection for children in typhoid endemic regions," said Dr. Emmanuel Mugisha, Global Director of Vaccine Implementation and Director of TyVAC at PATH, a consortium that aims to accelerate the introduction of TCVs in Gavi-eligible typhoid-endemic countries. "PATH congratulates EuBiologics on this milestone and is proud of the work we've done together to strengthen the TCV toolkit." Typhoid is a serious and potentially life-threatening illness that primarily impacts children younger than 15 years of age in Asia and sub-Saharan Africa. The Global Burden of Disease Study estimated that typhoid caused approximately 6.2 million cases and 72,000 deaths globally in 2023. While typhoid is treatable with antibiotics, drug-resistant typhoid is increasing, raising the urgency for preventative measures including TCVs and improvements to water, sanitation, and hygiene. Millions of children have already been reached through TCV introduction campaigns worldwide. About PATH PATH is a global nonprofit dedicated to achieving health equity. With nearly 50 years of experience forging multisector partnerships, and with expertise in science, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales up innovative solutions to the world's most pressing health challenges. For more information, visit https://www.path.org. About EuBiologics Co., Ltd. EuBiologics Co., Ltd., headquartered in Seoul, Republic of Korea, is a specialized developer of both preventive and therapeutic vaccines. The company is focused on building a diverse pipeline that includes bacterial and viral vaccines for infectious disease prevention, as well as personalized therapeutic vaccines. EuBiologics Co., Ltd. is a major supplier of WHO-prequalified oral cholera vaccines through UNICEF procurement, playing a key role in the global public health market. Leveraging its proprietary vaccine platforms, the company is also advancing premium vaccine development and provides customized contract research and manufacturing services for biopharmaceutical products. For more information, please visit the website (http://eubiologics.com/eng/).